KR20150038593A - 교모세포종의 치료를 위한 조합 요법 - Google Patents

교모세포종의 치료를 위한 조합 요법 Download PDF

Info

Publication number
KR20150038593A
KR20150038593A KR20157005660A KR20157005660A KR20150038593A KR 20150038593 A KR20150038593 A KR 20150038593A KR 20157005660 A KR20157005660 A KR 20157005660A KR 20157005660 A KR20157005660 A KR 20157005660A KR 20150038593 A KR20150038593 A KR 20150038593A
Authority
KR
South Korea
Prior art keywords
vegf
antibody
vegf antibody
patient
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157005660A
Other languages
English (en)
Korean (ko)
Inventor
아샤 다스
안나 마리아 아바호 기하로
라우렌 아브레이
조셉 가르시아
마갈리 힐톤
야닉 켈로귄
니콜라 무어
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48985869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150038593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20150038593A publication Critical patent/KR20150038593A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
KR20157005660A 2012-08-07 2013-08-06 교모세포종의 치료를 위한 조합 요법 Ceased KR20150038593A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261680672P 2012-08-07 2012-08-07
US61/680,672 2012-08-07
US201261714438P 2012-10-16 2012-10-16
US61/714,438 2012-10-16
US201361760763P 2013-02-05 2013-02-05
US61/760,763 2013-02-05
PCT/US2013/053841 WO2014025813A1 (en) 2012-08-07 2013-08-06 Combination therapy for the treatment of glioblastoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002046A Division KR20180011356A (ko) 2012-08-07 2013-08-06 교모세포종의 치료를 위한 조합 요법

Publications (1)

Publication Number Publication Date
KR20150038593A true KR20150038593A (ko) 2015-04-08

Family

ID=48985869

Family Applications (3)

Application Number Title Priority Date Filing Date
KR20157005660A Ceased KR20150038593A (ko) 2012-08-07 2013-08-06 교모세포종의 치료를 위한 조합 요법
KR1020187002046A Ceased KR20180011356A (ko) 2012-08-07 2013-08-06 교모세포종의 치료를 위한 조합 요법
KR1020197020608A Ceased KR20190088571A (ko) 2012-08-07 2013-08-06 교모세포종의 치료를 위한 조합 요법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187002046A Ceased KR20180011356A (ko) 2012-08-07 2013-08-06 교모세포종의 치료를 위한 조합 요법
KR1020197020608A Ceased KR20190088571A (ko) 2012-08-07 2013-08-06 교모세포종의 치료를 위한 조합 요법

Country Status (15)

Country Link
US (2) US20150148585A1 (enExample)
EP (2) EP3446709A1 (enExample)
JP (4) JP6464085B2 (enExample)
KR (3) KR20150038593A (enExample)
CN (1) CN104507498A (enExample)
AU (3) AU2013299724A1 (enExample)
BR (1) BR112015002681A2 (enExample)
CA (1) CA2880767A1 (enExample)
HK (1) HK1204993A1 (enExample)
IL (2) IL237028B (enExample)
MX (1) MX360189B (enExample)
RU (1) RU2015104001A (enExample)
SG (1) SG11201500903XA (enExample)
WO (1) WO2014025813A1 (enExample)
ZA (1) ZA201500811B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201701380TA (en) 2013-03-15 2017-04-27 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US10617755B2 (en) * 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10100115B2 (en) * 2014-02-14 2018-10-16 Macrogenics, Inc. Methods for the treatment of vascularizing cancers
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
EP3139956A4 (en) * 2014-05-07 2017-11-29 Medimmune, LLC Methods of using anti-ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102360693B1 (ko) 2014-07-11 2022-02-08 벤타나 메디컬 시스템즈, 인코포레이티드 항-pd-l1 항체 및 이의 진단 용도
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3638245A1 (en) 2017-06-12 2020-04-22 Agios Pharmaceuticals, Inc. Methods of treating brain tumors using combination therapy
CA3067035A1 (en) 2017-06-12 2018-12-20 Agios Pharmaceuticals, Inc. Methods of treating brain tumors using combination therapy
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
PT1695985E (pt) 1997-04-07 2011-06-06 Genentech Inc Métodos para formar anticorpos humanizados por mutagénese aleatória
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP2012524083A (ja) * 2009-04-20 2012-10-11 ジェネンテック， インコーポレイテッド アジュバント癌治療
SG183414A1 (en) * 2010-02-23 2012-09-27 Genentech Inc Anti-angiogenesis therapy for the treatment of ovarian cancer
EP2608799B1 (en) * 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy

Also Published As

Publication number Publication date
JP2018008946A (ja) 2018-01-18
RU2015104001A (ru) 2016-09-27
US20150148585A1 (en) 2015-05-28
US20200086139A1 (en) 2020-03-19
IL263661A (en) 2019-01-31
HK1204993A1 (en) 2015-12-11
WO2014025813A1 (en) 2014-02-13
JP2021138704A (ja) 2021-09-16
AU2016244262A1 (en) 2016-11-03
JP2015525798A (ja) 2015-09-07
JP2019147812A (ja) 2019-09-05
KR20190088571A (ko) 2019-07-26
SG11201500903XA (en) 2015-03-30
AU2013299724A1 (en) 2015-02-26
ZA201500811B (en) 2016-10-26
EP2882454A1 (en) 2015-06-17
AU2018253461A1 (en) 2018-11-15
EP2882454B1 (en) 2018-10-10
MX360189B (es) 2018-10-24
CA2880767A1 (en) 2014-02-13
JP6464085B2 (ja) 2019-02-06
EP3446709A1 (en) 2019-02-27
AU2016244262B2 (en) 2018-07-26
MX2015001627A (es) 2015-06-23
IL237028B (en) 2019-03-31
KR20180011356A (ko) 2018-01-31
BR112015002681A2 (pt) 2018-08-28
CN104507498A (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
AU2016244262B2 (en) Combination therapy for the treatment of glioblastoma
JP6640288B2 (ja) 卵巣癌の治療のための併用療法
JP2020059713A (ja) 膠芽腫治療のための併用療法

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20150304

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160715

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170626

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160715

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170626

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170116

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20171024

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170925

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170626

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170116

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160715

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180122

PJ0201 Trial against decision of rejection

Patent event date: 20180122

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20171024

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20170626

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190329

Appeal identifier: 2018101000304

Request date: 20180122

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101000304; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180122

Effective date: 20190329

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190329

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180122

Decision date: 20190329

Appeal identifier: 2018101000304

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20190531

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20190531

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2018101000304

Request date: 20180122

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190329